Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Adults seeking the strongest available weight-loss outcome in a brand-name SKU Adults with obesity and moderate-to-severe OSA (cross-listed indication) Adults with pre-diabetes and obesity who want T2D progression prevention Clients who plateaued on a semaglutide SKU and want a tirzepatide trial Clients comfortable with weekly subcutaneous injection In SURMOUNT-5, a 72-week head-to-head trial sponsored by Eli Lilly, adults on Zepbound (tirzepatide) achieved 20.2% mean body weight loss, compared with 13.7% for adults on Wegovy (semaglutide)
This kind of ongoing GLP-1 support includes regular check-ins with your provider, dosing adjustments based on how your body responds, help managing side effects when they come up, and guidance that goes beyond the medication itself
Fixing that upstream fixes everything else
First, participants were asked about their experience with GLP-1 drugs (see Table 1)
However, experts raise concerns about the safety and efficacy of this approach
